ArticleCell reports2019
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 2 pooled it
7.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Pooled it
- Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.Annals of oncology : official journal of the European Society for Medical Oncology · 2020Pooled it
- Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.The Lancet. Oncology · 2020Trial
- Breast cancer genomic subtype-specific copy number alterations in metastases.Scientific reports · 2026Article
- High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities.Nature communications · 2026Article
- The evolving landscape of brain metastasis: volume II.Trends in cancer · 2026Review
- Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties.Exploration of targeted anti-tumor therapy · 2026Review
- p53 inactivation drives breast cancer metastasis to the brain through SCD1 upregulation and increased fatty acid metabolism.Nature genetics · 2026Article
- Clinically actionable alterations in Indian breast cancer patients derived through whole transcriptome sequencing.The Indian journal of medical research · 2026Review
- The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy.International journal of molecular sciences · 2025Article
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- Genomic and immune profiling of breast cancer brain metastases.Acta neuropathologica communications · 2025Article
- Re-epithelialization of cancer cells increases autophagy and DNA damage: Implications for breast cancer dormancy and relapse.Science signaling · 2025Article
- Distant Metastases of Breast Cancer Resemble Primary Tumors in Cancer Cell Composition but Differ in Immune Cell Phenotypes.Cancer research · 2025Article
- Prevention of liver metastasis via the pharmacological suppression of AMIGO2 expression in tumor cells.Scientific reports · 2024Article
- Organ-Specific Immune Setpoints Underlie Divergent Immune Profiles across Metastatic Sites in Breast Cancer.Cancer immunology research · 2024Article
- A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features.Nature medicine · 2024Article
- Resolving tumor evolution: a phylogenetic approach.Journal of the National Cancer Center · 2024Review
- Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions.Current oncology reports · 2024Review
- Global post-mortem tissue donation programmes to accelerate cancer research.Nature reviews. Cancer · 2024Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 11 institutions in 4 countries.
Leticia De Mattos-ArrudaDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona 08035, Spain.
Stephen-John SammutDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Edith M RossDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Rachael Bashford-RogersDepartment of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.
Erez GreensteinDepartment of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
Havell MarkusCenter for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ 85004, USA; Mayo Clinic Center for Individualized Medicine, Scottsdale, AZ, USA.
Sandro MorganellaDepartment of Medical Genetics, The Clinical School, University of Cambridge, Cambridge CB2 0QQ, UK.
Yvonne TengCancer Molecular Diagnosis Laboratory, NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
Yosef MaruvkaThe Broad Institute, Cambridge, MA 02142, USA; Massachusetts General Hospital Cancer Center and Department of Pathology, Charlestown, MA 02129, USA.
Bernard PereiraDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Oscar M RuedaDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Suet-Feung ChinDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Tania Contente-CuomoCenter for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ 85004, USA; Mayo Clinic Center for Individualized Medicine, Scottsdale, AZ, USA.
Regina MayorVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona 08035, Spain; Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.
Alexandra AriasVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona 08035, Spain; Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.
H Raza AliDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Wei CopeDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Daniel TiezziDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Aliakbar DariushInstitute of Astronomy, University of Cambridge, Cambridge CB3 0HA, UK.
Tauanne Dias AmaranteDepartment of Medical Genetics, The Clinical School, University of Cambridge, Cambridge CB2 0QQ, UK.
Dan ReshefDepartment of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
Nikaoly CiriacoDepartment of Pathology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Elena Martinez-SaezSpanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain; Department of Pathology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Vicente PegSpanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain; Department of Pathology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain; Translational Molecular Pathology, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Santiago Ramon Y CajalSpanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain; Department of Pathology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain; Translational Molecular Pathology, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Javier CortesVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona 08035, Spain; Ramon y Cajal Hospital, 28034 Madrid, Spain.
George VassiliouCancer Molecular Diagnosis Laboratory, NIHR Cambridge Biomedical Research Centre, Cambridge, UK; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK; Wellcome Trust/MRC Cambridge Stem Cell Institute, Cambridge, UK.
Gad GetzThe Broad Institute, Cambridge, MA 02142, USA; Massachusetts General Hospital Cancer Center and Department of Pathology, Charlestown, MA 02129, USA.
Serena Nik-ZainalDepartment of Medical Genetics, The Clinical School, University of Cambridge, Cambridge CB2 0QQ, UK.
Muhammed MurtazaCenter for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ 85004, USA; Mayo Clinic Center for Individualized Medicine, Scottsdale, AZ, USA.
Nir FriedmanDepartment of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
Florian MarkowetzDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.
Joan SeoaneVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona 08035, Spain; Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain. Electronic address: jseoane@vhio.net.
Carlos CaldasDepartment of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Breast Cancer Programme, Cancer Research UK Cambridge Cancer Centre, Cambridge CB2 2QQ, UK. Electronic address: carlos.caldas@cruk.cam.ac.uk.
University of Cambridge · GBCancer Research UK Cambridge Center · GBVall d'Hebron Hospital Universitari · ESWeizmann Institute of Science · ILMassachusetts General Hospital · USMayo Clinic · USNIHR Cambridge Biomedical Research CentreVall d'Hebron Institute of OncologyCancer Research UK · GBTranslational Genomics Research Institute · USUniversitat Autònoma de Barcelona · ES
Funding
Cancer Research UK 16942Cancer Research UK 19274Cancer Research UK 23015Cancer Research UK 25815Medical Research Council MC_PC_12009
Abstract
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. The integrated genomic and immune landscapes show that metastases propagate and evolve as communities of clones, reveal their predicted neo-antigen landscapes, and show that they can accumulate HLA loss of heterozygosity (LOH). The data further identify variable tumor microenvironments and reveal, through analyses of T cell receptor repertoires, that adaptive immune responses appear to co-evolve with the metastatic genomes. These findings reveal in fine detail the landscapes of lethal metastatic breast cancer.
Indexed as
Gene Expression Regulation, NeoplasticMutationBiomarkers, TumorBreast NeoplasmsExome SequencingFemaleGene Expression ProfilingGenomicsHumansLoss of HeterozygosityNeoplasm MetastasisTumor MicroenvironmentBiomarkers, Tumorbreast cancerclade mutationsgenomic landscapesimmune landscapesimmunoeditingmetastasesmetastatic phylogeniesprivate mutationsstem mutationsTCR repertoire
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.